ArticleFrontiers in pharmacology2022

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome.

Cankun Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.